Skip to the content

Comparison of effective dose and lifetime risk of cancer Incidence of computed tomography attenuation correction acquisitions and radiopharmaceutical administration for myocardial perfusion imaging

Tootell, AK, Szczepura, K and Hogg, P 'Comparison of effective dose and lifetime risk of cancer Incidence of computed tomography attenuation correction acquisitions and radiopharmaceutical administration for myocardial perfusion imaging' , British Journal of Radiology . (In Press)

[img]
Preview
PDF
Download (681kB) | Preview
[img] Microsoft Word - Accepted Version
Restricted to Repository staff only

Download (53kB) | Request a copy

Abstract

Objectives: To measure the organ dose and calculate effective dose from CTAC acquisitions from four commonly used gamma camera SPECT/CT systems. Method: CTAC dosimetry data was collected using thermoluminescent dosimeters on GE’s Infinia Hawkeye four and single slice systems, Siemen’s Symbia T6 and the Philips Precedence. Organ and effective dose from the administration of 99mTc-tetrofosmin and 99mTc-sestamibi were calculated using ICRP reports 80 and 106. Using this data the lifetime biological risk was calculated. Results: The Siemens Symbia gave the lowest CTAC dose (1.8 mSv) followed by the GE Infinia Hawkeye single-slice (1.9 mSv), GE Infinia Hawkeye four-slice (2.5 mSv) and Philips Precedence (3.0). Doses were significantly lower than the calculated doses from radiopharmaceutical administration (11 mSv and 14 mSv for 99m Tc-Tetrofosmin and 99m Tc-Sestamibi respectively). Overall lifetime biological risks were lower suggesting that using CTAC data posed minimal to the risk to the patient. Comparison of data for breast tissue demonstrated a higher risk than that from the radiopharmaceutical. Conclusions: CTAC doses were confirmed to be much lower than from radiopharmaceutical administration. The localised nature of the CTAC exposure compared to the radiopharmaceutical biological distribution indicated dose and risk to the breast to be higher. Advances in knowledge: This research proved that CTAC is a comparatively low dose acquisition. However, it has been shown that there is increased risk to breast tissue especially in the younger patient. As per legislation justification is required and CTAC should only be used in situations that demonstrate sufficient net benefit.

Item Type: Article
Themes: Health and Wellbeing
Schools: Schools > School of Health Sciences > Centre for Health Sciences Research
Schools > School of Health Sciences
Journal or Publication Title: British Journal of Radiology
Publisher: British Institute of Radiology
Refereed: Yes
ISSN: 0007-1285
Funders: Non funded research
Depositing User: AK Tootell
Date Deposited: 09 Jul 2014 12:39
Last Modified: 30 Nov 2015 23:51
URI: http://usir.salford.ac.uk/id/eprint/32007

Actions (login required)

Edit record (repository staff only) Edit record (repository staff only)

Downloads

Downloads per month over past year